The aims of the UCSF-GIVI CFAR are to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS and to further the programs of NIH institutes by providing unique and effectively managed activities propelling HIV research. CFAR applies effective leadership, open communications, educational opportunities, sound resource management, and strategic planning to link CFAR members across sites and scientific disciplines. The Center's leadership is committed to proactive management, transparency and continued program monitoring, evaluation, and readjustment. CFAR maintains an effective partnership with the UCSF AIDS Research Institute and with the Center for AIDS Prevention Studies. To catalyze multidisciplinary research, the Center manages six scientific cores (Clinical and Population Sciences, Immunology, Virology, Specimen Banking, Pharmacology, and International). The Clinical and Population Sciences Core facilitates access to appropriate clinical cohorts. The International Core, focused on a growing portfolio in Uganda, will build in-country capacity and collaborate with the Fogarty International Center in training. Expansion to other African sites is expected. Core Directors are charged with member outreach and soliciting new investigators to take advantage of the cutting edge technologies and assays available within the cores. Success of the scientific cores is assessed by the quality of the multidisciplinary science they stimulate and by the publications and successful grants to which they contribute. The CFAR Administrative Core maintains an electronic network, including videoconferencing, to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems to monitor and report all CFAR funds, ensuring maximum CFAR effectiveness. The Developmental Core funds pilot an basic science grants. It supports the next generation of HIV science through mentored pilot grants and an extremely successful and ambitious formal mentoring program. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and the J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI027763-19S1
Application #
8129862
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
2010-09-01
Project End
2011-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
19
Fiscal Year
2010
Total Cost
$498,108
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Tang, Weiming; Liu, Chuncheng; Cao, Bolin et al. (2018) Receiving HIV Serostatus Disclosure from Partners Before Sex: Results from an Online Survey of Chinese Men Who Have Sex with Men. AIDS Behav 22:3826-3835
Clutton, Genevieve Tyndale; Jones, R Brad (2018) Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol 9:1452
Tamraz, Bani; Huang, Yong; French, Audrey L et al. (2018) A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clin Pharmacol Ther 104:949-956
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Kattah, Michael G; Milush, Jeffrey M; Burt, Trevor et al. (2018) Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 9:143
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
El-Sadr, Wafaa M; Goosby, Eric (2018) Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV. AIDS 32 Suppl 1:S1-S3
Streubel, Gundula; Watson, Ariane; Jammula, Sri Ganesh et al. (2018) The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. Mol Cell 70:371-379.e5
Dunkley, Emma; Ashaba, Scholastic; Burns, Bridget et al. (2018) ""I beg you…breastfeed the baby, things changed"": infant feeding experiences among Ugandan mothers living with HIV in the context of evolving guidelines to prevent postnatal transmission. BMC Public Health 18:188

Showing the most recent 10 out of 1541 publications